Avalanche Biotechnologies (AAVL) Tops Q2 EPS by 1c

Avalanche Biotechnologies (NASDAQ: AAVL) reported Q2 EPS of ($0.38), $0.01 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $203 thousand versus the consensus estimate of $760 thousand.

For earnings history and earnings-related data on Avalanche Biotechnologies (AAVL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery